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ABSTRACT
Nervous Necrosis Virus (NNV) is a devastating viral disease in marine aquaculture, causing significant
economic losses worldwide, including in Indonesia. The virus mainly infects larvae and juveniles of marine
fishes. This study aimed to determine the effectiveness of a recombinant vaccine from betanodavirus coat
proteins expressed in Escherichia coli fish against NNV infection in hybrid grouper. An RNA2 capsid protein
was selected and used as the recombinant vaccine. NNV-RNA2 gene was inserted into the protein expression
system vector of pET SUMO and cloned in cells of bacteria Escherichia coli strain BL-21. The results of blast
homology analysis exhibited that the amino acid sequence of the NNV-RNA2 showed high similarity with
Lates calcarifer encephalitis viral coat protein gene. E. coli expressing NNV-RNA2 protein was inactivated
using 0.03% formalin and mechanically inactivated by freeze-thaw and sonication methods. The inactivated
recombinant E. coli vaccine was then injected intramuscularly into hybrid grouper juveniles (single vaccine).
Subsequently, the juveniles were challenged with NNV at 7, 14, and 21 dpv (days post-vaccination). Injection
of 0.1 mL sterile PBS served as the control. Single vaccine applications using formalin-inactivated vaccines
resulted in higher antibody titers than those of mechanically-inactivated vaccines. Both vaccines were only
able to increase antibody titer up to 7 dpv. Therefore, re-vaccination (booster vaccine) was done on day-10
after the first vaccination using a formalin-inactivated vaccine. The booster vaccine could protect hybrid
grouper against NNV (P<0.05) at four weeks post-vaccination. However, the mortality of vaccinated and
control fish was not significantly different (P>0.05) after challenged with NNV for six weeks after. This
recombinant vaccine has the potential to be developed into a polyvalent vaccine by combining viral and
other bacterial vaccines in future research.
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INTRODUCTION
Over the past decade, aquaculture has grown at an
average annual growth rate of approximately 6% world-
wide despite many challenges. Viral diseases are one
of the major challenges that are threatening the sus-
tainable growth of finfish farming globally (Dhar et
al., 2013). The spread of viral diseases through inter-
national trade is now a proven threat to aquaculture.
Movement of animals showing no apparent clinical
signs or carrying sub-clinical infection, asymptomatic
carrier hosts, and shipment of contaminated/infected
eggs are threats to the sustainable growth of finfish
farming (Rodgers et al., 2011). Viral nervous necrosis
(VNN) is one of the viral diseases caused by Nervous
necrosis virus (NNV). It is classified as a major patho-
gen for several economically important fish species
worldwide (Lin et al., 2007). NNV belongs to the fa-
mily Nodaviridae and the genus Betanodavirus. NNV
is a small non-enveloped icosahedral virus with sizes
ranging between 25-30 nm and contains bi-segmented
single-strand positive RNA as the genetic material.
RNA1 (approximately 3.1 kb in length) encodes an
RNA-dependent RNA polymerase for viral replication,
whereas RNA2 (1.4 kb) encrypts a viral capsid pro-
tein (Iwamoto et al., 2004; Sommerset & Nerland,
2004). Betanodaviruses are divided into four
genogroups based on the partial sequences of RNA2:
barfin flounder nervous necrosis (BFNNV), tiger puffer
nervous necrosis (TPNNV), striped jack nervous ne-
crosis (SJNNV) and red-spotted grouper nervous ne-
crosis (RGNNV) (OIE, 2018).
In Indonesia, mass mortalities caused by NNV were
reported from various cultured marine fish such as
sea bass (Lates calcarifer) , humpback grouper
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(Cromileptes altivelis), tiger grouper (Epinephelus
fuscoguttatus), marbled grouper (E. polyphekadion),
coral trout grouper (Plectropomus leopardus), and hy-
brid grouper. The clinical signs of NNV are abnormal
swimming behaviors, including erratic, spiral or twirl-
ing, and belly-up swimming patterns with black body
color. These signs occurred on 1-2 days from initial
symptoms before the fish become weak because of
the decrease in appetite (Mahardika et al., 2015).
The infection route of NNV is arguably through
vertical transmission from infected broodstock to
their offspring, and horizontal transmission from sick
fish to healthy fish (Breuil et al., 2002). Prevention of
the disease during larval and juvenile stages may be
possible through broodstock management, disinfec-
tion of hatchery water or biosecurity measures. In
addition to controlling the disease, vaccination may
prove to be useful. Protective immunity has been
obtained in several fish species by using recombi-
nant betanodavirus coat proteins expressed in Escheri-
chia coli (Húsgaro et al., 2001; Tanaka et al., 2001; Yuasa
et al., 2002; Sommerset et al., 2005), and recombi-
nant betanodavirus coat proteins expressed in
baculoviruses (Thiery et al., 2006). However, the
availability of recombinant vaccine of betanodavirus
coat proteins expressed in Escherichia coli derived from
local Indonesian virus genes is limited. Cloning and
sequence analysis of the gene of betanodavirus pro-
tein coat and its vaccine production have been done
by Murwantoko & Nuraini (2008). The efficacy of the
VNN-DNA capsid vaccine was studied by Andriyani
(2012). However, the vaccines have not widely known
or distributed to fish farmers. Currently, the research
on a recombinant vaccine based on betanodavirus coat
proteins using local isolate from Bali has been done
at the Institute for Mariculture Research and
Fisheries Extension, Gondol. The present study was
the extended research to determine the effec-
tiveness of the recombinant vaccine from
betanodavirus coat proteins expressed in Escherichia
coli against VNN infection in hybrid grouper.
MATERIALS AND METHODS
Virus Stock
Viruses were obtained from the eyes and brains
of NNV naturally infected fish. Eye and brain samples
were separately homogenized in PBS (phosphate
buffer saline) at a ratio of 1: 5 v/v and centrifuged at
5,000 rpm for 10 min. The supernatant obtained was
filtered with a microfilter (0.45 m2). The obtained
filtrate was stored at -80°C and used as both a DNA
source and a challenge test.
Amplification of Target Gene
Genom of the virus stock was extracted with RNA
lysis buffer according to the manufacture protocol
(IQ 2000™). The primary designs for RNA2 were ob-
tained from several RNA sequence blasts: SJNNV
(AB025018.1), Dicentrarchus labrax NNV (JN189936.1),
Solea senegalensis betanodavirus (JN189919.1),
Senegalese sole Liberian betanodavirus
(JNFJ803923.1), and SJNNV gene for coat protein
(AB056572.1). The primary sequences are presented
in Table 1. Gene amplification was performed by re-
versing the RNA2 gene into DNA using the M-MLV
Reverse Transcriptase (Solis-Biodyene) kit at 50°C for
1 hour and 94 ºC for 7 minutes, followed by DNA
amplification in 40 cycles (one cycle consists of de-
naturation temperature at 94°C for 45 seconds,
annealing temperature at 52°C for 45 seconds and
extension temperature at 72°C for 90 seconds), and
the final extension at 72°C for 5 minutes. The ampli-
fication results were visualized in agar gel.
Cloning and Gene Expression
The construction of a recombinant Escherichia coli
expressing the coat protein was previously described
in detail by Mahardika & Mastuti (2015) for GSDIV
(grouper sleepy disease iridovirus). The same proce-
dure was applied to obtain a recombinant Escherichia
coli containing the coat protein gene of a betanodavirus
from diseased hybrid grouper “Cantik” (E.
fuscoguttatus X E. polyphekadion) with slight modifica-
tions. Briefly, results of the PCR amplification were
purified using a PCR purification kit and visualized in
agar gel to obtain a single band. The purification re-
sults were then ligated on a vector of pET SUMO
(Champion™ pET SUMO, Invitrogen). The ligation
results were transformed into the E. coli strain
Mach1™-T1R. The transformation process was done
by heat shock. The transformed bacteria were grown
on LB agar medium containing 50 ìg/mL of kanamy-
cin. Each growing colony was taken and re-cultured
on a 10 mL liquid LB medium containing 50 ìg/mL of
kanamycin to be used for DNA analysis and plasmid
stock. The colonies growing on the liquid LB were
extracted using a prepease minispin plasmid kit (USB,
Affimetrix), and its plasmid was amplified using the
target gene and SUMO primers. The known plasmids
carrying the target genes were then re-transformed
into E. coli strain BL-21 for expression purposes. The
transformants were grown in LB agar medium con-
taining kanamycin. Each growing colony was re-
cultured on a 10 mL liquid LB medium containing kana-
mycin and 0.1 mM IPTG (isopropyl-thio-b-D-galacto-
side) to induce proteins. The presence of protein
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expression in E. coli strain BL21 was confirmed by
SDS-PAGE analysis following the method, which was
previously described by Sommerset et al. (2005).
DNA Sequence Analysis
Twelve samples of PCR products from plasmids
on transformants E. coli strain Mach1 containing both
of the four samples of amplified ~1300 bp fragment
(RNA2-VNN primers) and eight samples of amplified
~1450 bp fragment (SUMO primers) were purified
using the Qiaquick PCR purification kit (Qiagen)
according to the manufacturer’s protocol. The puri-
fied DNA was sequenced using a DNA sequencer
(Macrogen) using two pair oligonucleotide primers,
ORFRNA2-26F/R1VNNRNA2 and SUMO F/R for se-
quence determination. The forward and reverse DNA
sequences generated in this study were then aligned
using BioEdit v7.1 software (Hall, 2011). DNA se-
quences were analyzed using  the Basic Local Align-
ment Search Tool (BLAST) to know its homology and
ORF Finder for the prediction of nucleotide acids.
Inactive Vaccine
A 50 g/mL colonies of induced E. coli strain BL-21
was inactivated by adding formalin to the final con-
centration of 0.03% and kept for a night, or mecha-
nically activated by fresh-taw method (at the tempera-
ture of -20°C and 42°C, respectively for 10 minutes
with 3 repetitions) and sonication (4 x 15 minutes).
Formalin was removed by centrifugation at 6000 rpm
for 5 min. Furthermore, the pellet was taken and re-
diluted to obtain the density of the bacteria equiva-
lent to the initial density (106 CFU/mL). Inactive
vaccines were stored at -20°C until further use.
Vaccination Test
Vaccination tests were performed on juveniles of
hybrid grouper “Cantik” with an average total length
of 12.52±2.45 cm. Vaccines were administered by
intramuscular injection with a dose of 0.1 mL/fish.
Vaccination test was done through two trials: the first
trial was aimed to know when the best time to do
booster vaccine. In the first trial, 525 of hybrid grou-
per fish were injected with the recombinant protein
NNV vaccine (A. NNV RNA2-6 with mechanical inacti-
vation, B. NNV RNA2-6 with formalin inactivation, C.
NNV RNA2-10 with mechanical inactivation, D. NNV
RNA2-10 with formalin inactivation), and E. injected
with PBS as the control. The fish were kept in a net
cage (0.5x0.5x1 m/hole) floating in a fiber tank with a
volume of 4 m3.  A total of five fish per treatment
were sampled at 5, 10, and 15 days after vaccination
to analyze their antibody titers (OD). The other 10
and 20 fish (total 30 fish) per treatment were sampled
at 7, 14, and 21 days after vaccination for challenge
tests against NNV inocula. The Relative Percent Sur-
vival (RPS) of fish during the virus challenge test was
calculated using the formula (Kai & Chi, 2008):
where:
V = percent cumulative mortality of vaccinated group
C = percent cumulative mortality of the control group
A total of 270 healthy hybrid “Cantik” grouper
were used on the second trial. Ninety fish from each
group were injected with recombinant protein NNV
vaccine isolates of NNV RNA2-6, isolates of NNV
RNA2-10 with mechanical or formalin inactivation
vaccine according to the percentage of RPS on the
first trial, and PBS as a control. The booster was done
at the time according to antibody titer test results at
the first trial. The fish were kept in a net cage
(0.5×0.5×1 m/hole) floating in a fiber tank with a
volume of 4 m3. The 30 fish were subsequently
challenged with NNV inocula on the two, four, and
six weeks after the booster vaccine. The other five
fish per each treatment were sampled at 2 and 4 weeks
after vaccination to analyze their antibody titers. The
mortality of fish during the challenge test was statis-
tically calculated by the Anova test.
The Enzyme-Linked Immunosorbent Assay
(ELISA)
Blood samples were left overnight at 4°C to
coagulate, centrifuged (6000 rpm for 5 min), and sera
collected, aliquoted, and stored at -20°C. Elisa analy-
sis was performed following the procedures previ-
ously developed by Jaramillo et al. (2016) and proce-
dures developed by Aquatic Diasnotic Ltd. Briefly,
rNNV RNA-6 or rNNV RNA-10 was diluted in carbo-
nate-bicarbonate buffer (15 mM Na
2
CO
3
, 35 mM
NaHCO
3
, pH 9.6) to 10 µg/ mL, and 96-well microtitre
Table 1. The primary sequences used to amplify the targeted genes
Oligonucleotide sequence (5’ to 3’ direction) Expected size of amplicons
RNA2 ORFRNA2 -26F ATGGTACGCAAAGGTGATAAGAAAWTGRCA 1,300 bp
R1VNNRNA2 TTAGTTTTCCGAGTCAACMCKGGTG
Genomic region
 
100 x 
C
V1
RPS


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plates (Nunc, Roskilde, Denmark) were coated with
150 µL/well overnight at 22°C. The plates were post-
coated with 100 µL of 1% PBS-BSA and incubated at
22°C for three hours. A 50 uL of serum sample was
then added to each well and incubated at 22°C for
one night (one sample made in duplo). All wells were
washed three times with 100 µL PBS-Tween. Then,
50 µL anti-Asian sea bass (Lates calcarifer) IgM mono-
clonal antibody labeled with horseradish peroxidase
(Aquatic Diagnostics Ltd) was added in each well and
incubated at 22°C for one hour. After washing three
times with PBS-Tween, the binding was visualized
using 50 µL TMB-ELISA (Serva). The reaction was
stopped after 10 min by the addition of 50 µL 2M
H
2
SO
4
. After equilibration for 30 min at 4°C, the opti-
cal density (OD) was measured at 450 nm in an
ELx800TM spectrophotometer.
RESULTS AND DISCUSSION
Target Gene Amplification
NNV genes obtained from the diseased fish’s eye
and brain were amplified with designed primers based
on the SJNNV gene in the region of the coat protein.
The optimization of amplification conditions produced
amplifiers with the correct size (1,300 bp) (Figure 1).
Some researchers also used the RNA2 gene as the
target gene for the vaccine (Húsgaro et al., 2001;
Thiery et al., 2006; Murwantoko & Nuraini, 2008; Kim
et al., 2015).
Ligation and Transformation of NNV RNA2
Gene
The ligation of the NNV-RNA2 gene in the vector
of pET SUMO, and then transformed into the cell E.
coli strain Mach1 produced several colonies, one of
which (the isolate E. coli Mach1-D1) was taken for re-
transformed into the cell of E. coli strain BL21. One
colony of E. coli strain Mach1 and four colonies of
E. coli strain BL21 (colonies 6, 7, 9, and 10) were found
to carry recombinant plasmids by insertion of NNV-
RNA2 genes with the correct orientation. Insertion
of recombinant plasmid was indicated by a thick band
of 1,450 bp in PCR analysis using a combination of
forward/reverse primers of the pET SUMO and the
NNV-RNA2 gene (Figure 2) which we had successfully
developed in our previous research for the GSDIV-
MCP gene (Mahardika & Mastuti, 2015).
Coat Protein Expression
SDS-PAGE analysis of the purified E. coli-expressed
inclusion bodies showed a dominating band of
approximately 58 kDa (Figure 3), which was 10 kDa
higher than the molecular weight of recAHNV-C (in-
cluding an N-terminal His-Tag) (Sommerset et al.,
2005), and relatively lower than the molecular weight
of GSDIV-MCP with target DNA of 1,362 bp
(Mahardika & Mastuti, 2015).
DNA Sequence of NNV RNA2
NNV RNA2 gene sequencing was obtained throgh
partial nucleotide sequence (partial cds), i.e. 1,113 of
1,300 nucleotides (Figure 4). BLAST homologous
analysis showed that the NNV-RNA2 genes have simi-
larity up to 98% with the partial sequence of NNV:
Lates calcarifer encephalitis viral coat protein gene
(EU380202.1), complete genome sequence of dragon
grouper nervous necrosis coat protein gene
(AY721615.1), complete genome sequence of
red-spotted grouper nervous necrosis virus isolate
GMNNV-Korea coat protein mRNA (DQ116038.1),
complete genome sequence of red-spotted grouper
nervous necrosis virus isolate SpPm-IAusc1586 10
capsid protein gene (KC896562.1), complete genome
sequence of tiger grouper nervous necrosis virus iso-
late TGNNV0809-Tuaran-Malaysia-1 coat protein (Cp)
 
1,000 bp 
1,500 bp 
1,300 bp 
Figure 1. Agarose gel visualization of the NNV RNA2 gene shows the ex-
pected amplicon size of 1,300 bp. M: 100 bp DNA ladder, Line 1-6:
samples of eye and brain of diseased fish suffering VNN infection.
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mRNA (HQ859945.1), and complete genome sequence
of tiger grouper nervous necrosis virus isolate
TGNNV0708-Gondol-Indonesia-2coat protein (Cp)
mRNA (HQ859972.1).
Vaccination Test
The first vaccination test indicated that formalin-
inactivated crude RNA2 recombinant protein had the
potential to induce fish immunity against VNN infec-
tion. Result of the challenge test with NNV having a
lethal dose of 80% showed that the recombinant pro-
tein vaccine (NNV RNA2-isolates 6 and 10) inactivated
with formalin had a relative percent survival value (RPS)
of 40.0% and 53.33% higher than that of the recombi-
nant protein vaccine that was mechanically-inactivated
and the control treatment in the first-week post-vac-
cination. However, the vaccine’s ability to maintain
the specific immunity of hybrid grouper fish decreased
dramatically in the second and third weeks after
vaccination indicated by a low RPS value (Table 2).
Results of the challenge test with the NNV virus
were similar to the results of the antibody titer shown
in Figure 5. The absorbance value of blood serum of
the hybrid grouper ‘Cantik’ vaccinated with NNV-RNA2
isolates 6 and 10, which were inactivated either for-
malin or mechanically methods were higher than that
of the control. However, these antibody titers de-
creased after 14 days post-vaccination. Formalin-in-
activated vaccine gave higher antibody titers than that
mechanically inactivated vaccines. Therefore, it was
necessary to booster/re-vaccination at 14 days after
vaccination. The timing of this booster was based
on the antibody titer results, whereby the antibody
titer peaks at 10 days after the vaccination and was
low at day 14 dpv. The booster vaccine was given in
the event of a decrease in the antibody titer. The
booster was expected to increase the antibody titer
and maintain it for an extended period.
In the second experiment, re-vaccination (booster)
was done at 14 days after the first vaccination using
 
Primer: F-SUMO & 
R1VNNRNA2 
Primer: R-SUMO & 
ORFRNA2-26F 
1,450 bp 
1     2      3      4      5     M     1       2      3      4       5   
1,500 bp 
Figure 3. Escherichia coli-expressed recombinant NNV-RNA2 coat protein ana-
lyzed by SDS-PAGE. M: molecular weight marker (Broad Range preci-
sion protein standard); lane 1, purified rNNV RNA2-10, lane 2: purified
rNNV RNA2-6, CAT: purified rCAT SUMO.
Figure 2. PCR confirmation of the recombinant plasmid for correct orientation
using combination primer of pET SUMO and primer of NNV-RNA2. Line
1-4: plasmids of E. coli strain BL2- isolate number of 6, 7, 9, and 10, Line
5: plasmid of E. coli strain Mach1-isolate D1.
 
  50 kDa 
  60 kDa 
  70 kDa 
    1             2         CAT       M 
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formalin-inactivated vaccine (Table 3). The per-
centage of fish mortality on both vaccinated groups
after being infected with the NNV at 2 weeks after
the booster vaccine was significantly different
(P<0.05) with control. The percentage of fish mor-
tality in the both of vaccinated groups increased at 4
and 6 weeks after the booster, but it was still signifi-
cantly different (P<0.05) with the control. These re-
sults indicated that the booster increased the immu-
nity of hybrid grouper against VNN.
Table 2. RPS value of vaccinated-hybrid grouper “Cantik” after challenged with NNV-inocula
Number 
of fish
Mortality 
(%)
RPS
Number 
of fish
Mortality 
(%)
RPS
Number 
of fish
Mortality 
(%)
RPS
1 20 45 40.0 20 60 20.0 20 80 -
2 10 80 20.0 10 70 - 10 80 -
1 20 35 53.33 20 55 26.67 20 75 6.25
2 10 60 40.0 10 60 14.29 10 90 (12.5)
1 20 50 33.33 20 65 13.33 20 80 -
2 10 80 20.0 10 70 - 10 80 -
1 20 60 20.0 20 60 20.0 20 75 6.25
2 10 70 30.0 10 60 14.24 10 100 (25.0)
1 20 75 - 20 75 - 20 80 -
2 10 100 - 10 70 - 10 80 -
PBS as control -
14 days post-vaccination 21 days post-vaccination
E. coli 
contained 
protein 
recombinant 
of RNA2 NNV 
Mechanical
Formalin
E. coli 
contained 
protein 
recombinant 
of RNA2 NNV 
Mechanical
Formalin
Number 
of 
trial
Treatments
Method of
inactivation
Seven days post-vaccination
Figure 4. Partial coding sequence (partial cds) of gene encoding NNV-RNA2.
1 G C C G C T A A T C C G C A A C C C C G C C G A C G T G C T A A C A A T C G T C G G C G T
M A N P Q P R R R A N N R R R
46 A G T A A C C G C T C T G A C G C A C C T G T G T C T A A G G C C T C G A C T G T G A C T
S N R S D A P V S K A S T V T
91 G G A T T T G G G C G T G G G G C C A A T G A C G T C C A T C T C T C A G G T A T G T C G
G F G R G A N D V H L S G M S
136 A G A A T C T C C C A G G C C G T C C T C C C A G C C G G G A C A G G A A C A G A C G G A
R T S Q A V L P A G T G T D A
181 T A C G T T G T T G T T G A C G C A A C C A T C G T C C C C G A C C T C C T G C C A C G A
Y V V V D A T I V P D L L P R
226 C T G G G A C A T G C T G C T A G A A T C T T C C A G C G A T A C G C T G T T G A A A C A
L G H A A R I F Q R Y A V E T
271 C T G G A G T T T G A A A T T C A G C C A A T G T G C C C C G C A A A C A C G G G C G G T
L E F E I Q P M C P A N T G G
316 G G T T A C G T T G C T G G C T T C C T G C C T G A T C C A A C T G A C A A C G A T C A C
G Y V A G F L P D P T D N D H
361 A C C T T C G A C G C G C T T C A A G C A A C T C G T G G T G C A G T C G T T G C C A A A
T F D A L Q A T R G A V V A K
406 T G G T G G G A A A G C A G A A C A G T C C G A C C C C A G T A C A C C C G C A C A C T C
W W E S R T V R P Q Y T R T L
451 C T C T G G A C C T C G T C G G G A A A G G A G C A G C G T C T C A C G T C A C C T G G T
L W T S S G K E Q R L T S P G
496 C G G C T G A T A C T C C T G T G T G T C G G C A A C A A C A C T G A T G T G G T C A A C
R L I L L C V G N N T D V V N
541 G T G T C A G T G C T T T G T C G C T G G A G T G T T C G A C T G A G C G T T C C A T C T
V S V L C R W S V R L S V P S
586 C T G G A G A C A C C T G A G G A G A C C A C C G C T C C C A T C A T G A C A C A A G G T
L E T P E E T T A P I M T Q G
631 T C C C T G T A C A A C G A T T C C C T T T C C A C A A A T G A C T T C A A G T C C A T C
S L Y N D S L S T N D F K S I
676 C T C C T A G G A T C C A C A C C A C T G G A T A T T G C C C C T G A T G G A G C A A T C
L L G S T P L D I A P D G A I
721 T T C C A G C T G G A T C G T C C G C T G T C C A T T G A C T A C A G C C T T G G A A C T
F Q L D R P L S I D Y S L G T
766 G G A G A T G T T G A C C G T G C T G T T T A C T G G C A C C T C A A G A A G T T T G C T
G D V D R A V Y W H L K K F A
811 G G A A A T G C T G G C A C A C C T G C A G G C T G G T T T C G C T G G G G C A T C T G G
G N A G T P A G W F R W G I W
856 G A C A A C T T C A A C A A G A C G T T C A C A G A T G G C G T T G C C T A C T A C T C T
D N F N K T F T D G V A Y Y S
901 G A T G A G C A G C C C C G T C A A A T C C T G C T G C C T G T T G G C A C T G T C
D E Q P R Q I L L P V G T V
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This study selected the production of recombi-
nant NNV protein due to the experienced difficulty in
producing viral vaccines originating from the results
of viral propagation in cell culture and the multiplica-
tion of viruses in fish (Mahardika & Mastuti, 2015).
Although the initial production costs of making re-
combinant vaccines are very expensive, the cost of
mass production of these types of vaccines is cheaper,
and the use of viral proteins is safer than the use of
whole-body viruses (Clark & Cassidy-Hanley, 2005;
Mahardika et al., 2018). Kim et al. (2015) also reported
the efficacy of recombinant protein vaccines based
on CFPS (Cell-free protein synthesis). This recombi-
nant protein (rNNV-CP) was successfully expressed
and purified using CFPS. Administering rNNVCP at a
dose of 20 µg/fish successfully protected seven band
groupers from NNV infection. The expression of NNV
coat protein in tobacco chloroplasts has also been
successfully carried out for oral vaccines to induce
immunities in seven band grouper. A plant-based
vaccine was effectively induced immune response and
protected groupers against NNV (Cho et al., 2018).
The application of recombinant capsid gene NNV,
which namely r-FNCP vaccine mixed with complete
adjuvant at a dose of 50 µg per a fish, was able to
protect Asian sea bass from nodavirus infection re-
sulting on RPS value of 76% (Vimal et al., 2014). Vacci-
nation with an oil-emulsified recombinant SJNNV (rT2)
capsid protein could reduce the death of turbot fish
against NNV infection with a value of RPS up to 83%
(Húsgaro et al., 2001). Recombinant proteins
(recAHNV-C) vaccine was also reported to provide
better protection against NNV virus infections in tur-
bot juvenile fish (RPS up to 67%) than that of pAHNV-
C DNA vaccines (Sommerset et al., 2005). This re-
combinant protein vaccine could also be applied to-
gether with other recombinant protein vaccines, such
as the iridovirus recombinant protein vaccine
(Mahardika et al., 2018). Both of these recombinant
vaccines (bivalent vaccines) were reported to be able
to induce MHC class 1 from the larva of the coral
trout grouper (Plectropomus leopardus). Bivalent
vaccines were also reported to be able to increase
the anti-NNV antibody serum titer more than one
month after the vaccination (Huang et al., 2017).
Our results showed that the recombinant protein
vaccine could only protect hybrid groupers up to one
month after the booster vaccine. It was indicated by
the mortality of fish that was not significantly
Figure 5. The value of OD (optical density) ELISA for blood serum of vaccinated hybrid
grouper “Cantik.”
Table 3. Average mortality of vaccinated-hybrid “Cantik” grouper following challenged with
NNV at 2, 4, and 6 weeks post booster
Note: Values in the same column with the same superscripts are not significantly different (P>0.05)
Treatments
Two weeks
post booster
Four weeks
post booster
Six weeks
post booster
E. coli  contained protein recombinant
of RNA2 NNV (isolate 6)
47.62 ± 8.25a 66.67 ± 8.25a 66.67 ± 8.25a
E. coli  contained protein recombinant
of RNA2 NNV (isolate 10)
57.14 ± 14.29a 80.95 ± 8.25b 61.90 ± 8.25a
PBS (as control) 85.71 ± 14.29b 100 ± 0c 85.72 ± 0b
0
0.05
0.1
0.15
0.2
0.25
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different (P>0.05) after the challenge test with the
NNV virus at 6 weeks. This indicated that the vaccine
was not enough to make and maintain a specific
immune response until 6 weeks after vaccination.
Similar results were also reported by Husgaro et al.
(2001), where the mortality of vaccinated turbot fish
was higher than that of the control group at 5 weeks
after vaccination.
CONCLUSIONS
Protein recombinant NNV RNA 2 vaccine has been
successfully produced. The application of E. coli bac-
teria carrying recombinant NNV RNA2 protein inacti-
vated using formalin method able to increase the
antibody titers resulting in higher RPS values com-
pared to the inactivation of E. coli bacteria through
the mechanical method. The booster used on day 10
was able to reduce fish mortality (P<0.05) up to 6
weeks after the vaccine administration. Overall, the
recombinant NNV RNA2 protein can be used as a
vaccine to prevent grouper mortality from NNV virus
infection. This recombinant vaccine has the poten-
tial to be developed into a bivalent or polyvalent
vaccine by combining viral and other bacterial
vaccines in future research.
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